References
- Mendelsohn , J. and Baselga , J. 2003 . Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer . J. Clin. Oncol. , 21 : 2787 – 2799 .
- Ciardiello , F. , De Vita , F. , Orditura , M. , De Placido , S. and Tortora , G. 2003 . Epidermal growth factor receptor tyrosine kinase inhibitors in late stage clinical trials . Exp. Opin. Emerg. Drugs , 8 : 501 – 514 .
- Vansteenkiste , J. F. 2004 . Gefitinib (iressa): A novel treatment for non‐small‐cell lung cancer . Expert Rev. Anticancer Ther. , 4 : 5 – 17 .
- Bonomi , P. 2003 . Erlotinib: A new therapeutic approach for non‐small‐cell lung cancer . Expert Opin. Invest. Drugs , 12 : 1395 – 1401 .
- Kobayashi , S. , Boggon , T. J. , Dayaram , T. , Jaenne , P. A. , Kocher , O. , Meyerson , M. , Johnson , B. E. , Eck , M. J. , Tenen , D. G. and Halmos , B. 2005 . EGFR mutation and resistance of non‐small‐cell lung cancer to gefitinib . N. Engl. J. Med. , 352 : 786 – 792 .
- Blackhall , F. , Ranson , M. and Thatcher , N. 2006 . Where next for gefitinib in patients with lung cancer? . Lancet Oncology , 7 : 499 – 507 .
- Marshall , J. 2006 . Implications of the mechanism of epidermal growth factor receptor inhibitors . Cancer , 107 : 1207 – 1218 .
- Johnson , D. H. 2006 . Targeted therapies in combination with chemotherapy in non‐small cell lung cancer . Clin. Cancer Res. , 12 : 4451s – 4457s .
- Chandregowda , V. , Rao , G. V. and Reddy , G. C. 2007 . One‐pot conversion of 2‐nitrobenzonitriles to quinazoline‐4(3H)‐ones and synthesis of gefitinib and erlotinib hydrochloride . Heterocycles , 71 : 39 – 48 . and references cited therein
- Knesl , P. , Röseling , D. and Jordis , U. 2006 . Improved synthesis of substituted 6,7‐dihydroxy‐4‐quinazoline amines: Tandutinib, erlotinib, and gefitinib . Molecules , 11 : 286 – 287 . and references cited therein